Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
BETA.NS
BuyPremium GrowerBeta Drugs Limited · Healthcare · India · $228M · Avg Vol: $732K/d
72
StockRankGet insider-trade alerts
Q
64
V
24
M
78
P/E (TTM)
47.8x
ROE
16.9%
D/E
0.6x
Dividend %
—
COMPANY DESCRIPTION
Beta Drugs Limited develops, manufactures, and sells anti-cancer bulk drugs and finished dosages in India. The company offers cosmeceutical and oncology products. It also manufactures active pharmaceutical ingredients (API) and pharmaceutical formulation intermediates (PFI).
FINANCIAL SUMMARY (INR)
| Year | 2022 | 2023 | 2024 | 2025 | 2026 | CAGR | TTM |
|---|---|---|---|---|---|---|---|
| Revenue | — | 2.3B | 3.0B | 3.6B | 3.8B | 19.2% | 4.1B |
| EPS (INR) | — | 30.43 | 37.90 | 42.02 | 40.92 | 10.4% | 44.23 |
| Shares | 10.1M | 10.1M | 10.1M | 10.1M | — | +0.0% | 10.1M |
| Debt | — | 203.3M | 147.1M | 1.4B | 1.5B | 93.7% | 1.5B |
| Equity | — | 1.2B | 1.6B | 2.0B | 2.4B | 25.8% | — |
| Op CF | — | 233.8M | 309.3M | 361.7M | 372.9M | 16.8% | 374.1M |
| Inv CF | — | -190.7M | -139.7M | -357.2M | -513.9M | — | — |
| Fin CF | — | -24.7M | -74.9M | 1.2B | -80.7M | — | — |
Loading 1Y...
PRICE (1Y)-5.3%
SMA 50SMA 200
Close
$21.86
RSI (14)
33.9
52W High
$29.42
From 52W High
0.7%
SCORE BREAKDOWN
Quality
64
ROIC
19.4%89.7
ROE
16.9%85.1
GP/Assets
47.2%84.8
Op. Margin
18.3%80.5
FCF/Assets
-3.3%38.3
Piotroski
439.0
Int. Cover
5.2x52.0
D/E Ratio
0.60x24.7
Current Ratio
3.10x56.6
Value
24
P/E (TTM)
47.8x22.6
EV/EBITDA
27.5x23.4
P/FCF
—N/A
P/B
8.7x14.0
P/S
5.2x40.6
Div Yield
—N/A
Momentum
78
52W High %
74%57.2
RS 6M
90%96.3
SMA 50/200
1.38x95.7
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
—N/A
Q Growth
35%66.8
FUNDAMENTALS
Market Cap
$228M
P/E (Forward)
—
Gross Margin
57.1%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of BETA.NS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| BETA.NS | Beta Drugs Limited(you) | $228M | 72 | Buy |
| INDOCO.NS | Indoco Remedies Limited | $237M | 63 | Hold |
| HIKAL.NS | Hikal Limited | $320M | 74 | Buy |
| SAKAR.NS | Sakar Healthcare Limited | $268M | 79 | Buy |
| WINDLAS.NS | Windlas Biotech Limited | $248M | 84 | Strong Buy |
| GUFICBIO.NS | Gufic Biosciences Limited | $466M | 70 | Buy |
| INDSWFTLAB.NS | Ind-Swift Laboratories Limited | $356M | 80 | Strong Buy |
| SOLARA.NS | Solara Active Pharma Sciences Limited | $357M | 81 | Strong Buy |
| WANBURY.NS | Wanbury Limited | $91M | 70 | Buy |
| THEMISMED.NS | Themis Medicare Limited | $129M | 63 | Hold |
Peer medians: ROE 11.8% · P/E 42.5x · Gross margin 59.4%